Company Filing History:
1 out of 21 
1 out of 92 
Years Active: 2021
Title: Claus Scheidereit: Innovator in Genotoxic Stress Treatment
Introduction
Claus Scheidereit is a notable inventor based in Berlin, Germany. He has made significant contributions to the field of molecular medicine, particularly in the treatment of diseases associated with genotoxic stress.
Latest Patents
One of his key patents is titled "Selective inhibitors of genotoxic stress-induced IKK/NF-κB pathways." This patent outlines a method for treating diseases linked to genotoxic stress-induced activation of the IKK/NF-κB signaling pathway. The method involves administering a compound to a subject suffering from cancer that exhibits this specific activation.
Career Highlights
Claus Scheidereit has worked with prominent research institutions, including the Max Delbrück Center for Molecular Medicine in the Helmholtz Association and the Forschungsverbund Berlin e.V. His work has been instrumental in advancing our understanding of molecular mechanisms in cancer.
Collaborations
Throughout his career, he has collaborated with esteemed colleagues such as Michael Willenbrock and Peter Lindemann. These collaborations have further enriched his research and contributions to the field.
Conclusion
Claus Scheidereit stands out as an innovator in the realm of molecular medicine, particularly in developing treatments for cancer related to genotoxic stress. His work continues to influence the scientific community and offers hope for future advancements in cancer therapy.